Bris­tol My­ers flags an­oth­er PhI­II suc­cess for one of their top block­buster prospects, clear­ing a path to the FDA

Re­searchers for Bris­tol My­ers Squibb say they have cleared the sec­ond big Phase III hur­dle for their block­buster pso­ri­a­sis con­tender deu­cravac­i­tinib, clear­ing the path to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER